Current and future management of pediatric venous thromboembolism

American Journal of Hematology

Volumn 87, Issue SUPPL. 1, 2012, Pages

  Kerlin, Bryce A ^a,b,c  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; ARGATROBAN; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; RECOMBINANT PLASMINOGEN ACTIVATOR; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; CHILDHOOD DISEASE; CLINICAL TRIAL (TOPIC); FOLLOW UP; HIGH RISK PATIENT; HUMAN; IDIOPATHIC DISEASE; LOADING DRUG DOSE; MORTALITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; TREATMENT DURATION; VASCULAR ACCESS DEVICE; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGE FACTORS; ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITAL MORTALITY; HUMANS; INFANT; INJECTIONS, SUBCUTANEOUS; MALE; POSTTHROMBOTIC SYNDROME; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84859957253     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23131     Document Type: Review

References (106)

1. Raffini L, Huang YS, Witmer C, et al. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics 2009; 124: 1001-1008.
2. Vu LT, Nobuhara KK, Lee H, et al. Determination of risk factors for deep venous thrombosis in hospitalized children. J Pediatr Surg 2008; 43: 1095-1099.
3. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83: 1251-1257.
4. Setty BA, O'Brien SH, Kerlin BA. Pediatric venous thromboembolism in the United States: A tertiary care complication of chronic diseases. Pediatr Blood Cancer 2011.
5. Boulet SL, Amendah D, Grosse SD, et al. Health care expenditures associated with venous thromboembolism among children. Thromb Res 2011.
6. Tuckuviene R, Christensen AL, Helgestad J, et al. Pediatric venous and arterial noncerebral thromboembolism in Denmark: A nationwide population-based study. J Pediatr 2011; 159: 663-669.
7. Chan AK, Deveber G, Monagle P, et al. Venous thrombosis in children. J Thromb Haemost 2003; 1: 1443-1455.
8. Manco-Johnson MJ. How I treat venous thrombosis in children. Blood 2006; 107: 21-29.
9. Nowak-Gottl U, Junker R, Kreuz W, et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97: 858-862.
10. Price VE, Chan AK. Venous thrombosis in children. Expert review of cardiovascular therapy 2008; 6: 411-418.
11. Young G, Albisetti M, Bonduel M, et al. Impact of inherited thrombophilia on venous thromboembolism in children: A systematic review and meta-analysis of observational studies. Circulation 2008; 118: 1373-1382.
12. Chalmers E, Ganesen V, Liesner R, et al. Guideline on the investigation, management and prevention of venous thrombosis in children. Br J Haematol 2011; 154: 196-207.
13. Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 887S-968S.
14. Newall F, Barnes C, Ignjatovic V, et al. Heparin-induced thrombocytopenia in children. J Paediatr Child Health 2003; 39: 289-292.
15. Sutor AH, Massicotte P, Leaker M, et al. Heparin therapy in pediatric patients. Semin Thromb Hemost 1997; 23: 303-319.
16. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-172.
17. Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: A prospective cohort study. Pediatr Res 1994; 35: 78-83.
18. Punzalan RC, Hillery CA, Montgomery RR, et al. Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol 2000; 22: 137-142.
19. Schmugge M, Risch L, Huber AR, et al. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 2002; 109: E10.
20. Klenner AF, Lubenow N, Raschke R, et al. Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. Thromb Haemost 2004; 91: 719-724.
21. Ignjatovic V, Najid S, Newall F, et al. Dosing and monitoring of enoxaparin (low molecular weight heparin) therapy in children. Br J Haematol 2010; 149: 734-738.
22. Rajgopal R, Bear M, Butcher MK, et al. The effects of heparin and low molecular weight heparins on bone. Thromb Res 2008; 122: 293-298.
23. Shaughnessy SG, Young E, Deschamps P, et al. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995; 86: 1368-1373.
24. Dager WE, White RH. Low-molecular-weight heparin-induced thrombocytopenia in a child. Ann Pharmacother 2004; 38: 247-250.
25. Kuhle S, Massicotte P, Dinyari M, et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005; 94: 1164-1171.
26. Biss TT, Avery PJ, Brandao LR, et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood 2012; 119:868-873.
27. Nowak-Gottl U, Dietrich K, Schaffranek D, et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood 2010; 116: 6101-6105.
28. Hines RN, Gill JC. Warfarin Pharmacogenetics in Pediatric Patients. Research Portfolio Online Reporting Tools (RePORT). National Institutes of Health: National Institutes of Health; 2011.
29. Bovill EG, Soll RF, Lynch M, et al. Vitamin K1 metabolism and the production of des-carboxy prothrombin and protein C in the term and premature neonate. Blood 1993; 81: 77-83.
30. Schmidt B, Andrew M. Report of scientific and standardization subcommittee on neonatal hemostasis diagnosis and treatment of neonatal thrombosis. Thromb Haemost 1992; 67: 381-382.
31. Barnes C, Newall F, Ignjatovic V, et al. Reduced bone density in children on long-term warfarin. Pediatr Res 2005; 57: 578-581.
32. Biss T, Avery PJ, Walsh PM, et al. Warfarin treatment outcomes in children monitored at home with a point-of-care device. Thromb Haemost 2011; 105: 1103-1105.
33. Goldenberg NA, Branchford B, Wang M, et al. Percutaneous mechanical and pharmacomechanical thrombolysis for occlusive deep vein thrombosis of the proximal limb in adolescent subjects: Findings from an institution-based prospective inception cohort study of pediatric venous thromboembolism. J Vasc Interv Radiol 2011; 22: 121-132.
34. Goldenberg NA, Durham JD, Knapp-Clevenger R, et al. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood 2007; 110: 45-53.
35. Yee DL, Chan AK, Williams S, et al. Varied opinions on thrombolysis for venous thromboembolism in infants and children: findings from a survey of pediatric hematology-oncology specialists. Pediatr Blood Cancer 2009; 53: 960-966.
36. Bauer KA. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm 2001; 58 Suppl 2: S14-17.
37. Young G, Yee DL, O'Brien SH, et al. FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatr Blood Cancer 2011; 57: 1049-1054.
38. O'Brien SH, Lee H, Ritchey AK. Once-daily enoxaparin in pediatric thromboembolism: a dose finding and pharmacodynamics/pharmacokinetics study. J Thromb Haemost 2007; 5: 1985-1987.
39. Nohe N, Flemmer A, Rumler R, et al. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 1999; 158 (Suppl 3): S134-S139.
40. Matziolis G, Perka C, Disch A, et al. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int 2003; 73: 370-379.
41. Handschin AE, Trentz OA, Hoerstrup SP, et al. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 2005; 92: 177-183.
42. Madabushi R, Cox DS, Hossain M, et al. Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. J Clin Pharmacol 2011; 51: 19-28.
43. Young G, Boshkov LK, Sullivan JE, et al. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: An open-label, safety, efficacy, and pharmacokinetic study. Pediatr Blood Cancer 2011; 56: 1103-1109.
44. GlaxoSmithKline USA. Argatroban - Prescribing Information. GlaxoSmithKline USA; 2011.
45. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99: 830-839.
46. Young G, Tarantino MD, Wohrley J, et al. Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost 2007; 5: 1654-1659.
47. Forbes TJ, Hijazi ZM, Young G, et al. Pediatric catheterization laboratory anticoagulation with bivalirudin. Catheter Cardiovasc Interv 2011; 77: 671-679.
48. Young G. The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids. ClinicalTrials.gov:National Institutes of Health; 2011.
49. Boehringer Ingelheim Pharmaceuticals. Safety and Tolerability of Dabigatran Etexilate Solution in Children, 1 to < 12 Years of Age. ClinicalTrials.gov:National Institutes of Health; 2011.
50. Boehringer Ingelheim Pharmaceuticals. Safety and Tolerability of Dabigatran Etexilate in Adolescents. ClinicalTrials.gov: National Institutes of Health; 2011.
51. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-1814.
52. Wang H, Madhusudhan T, He T, et al. Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy. Blood 2011; 117: 5231-5242.
53. Furugohri T, Shiozaki Y, Muramatsu S, et al. Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models. Eur J Pharmacol 2005; 514: 35-42.
54. Furugohri T, Sugiyama N, Morishima Y, et al. Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system. Thromb Haemost 2011; 106.
55. Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007; 27: 1238-1247.
56. FDA. Integrated executive summary of FDA review for NDA, 21-686 Exanta. (Ximelagatran). FDA Executive Summary. Washington DC: Food and Drug Administration; 2004.
57. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
58. Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1, 3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): An oral, direct factor Xa inhibitor. J Med Chem 2005; 48: 5900-5908.
59. Bayer Healthcare AG. Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects. ClinicalTrials.gov: National Institutes of Health; 2011.
60. Bristol-Myers Squibb. Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter. ClinicalTrials.gov: National Institutes of Health; 2011.
61. Bristol-Myers Squibb. A Phase III Study of Apixaban in Patients With Atrial Fibrillation (AVERROES). ClinicalTrials.gov: National Institutes of Health; 2011.
62. Bristol-Myers Squibb. Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism. ClinicalTrials.gov: National Institutes of Health; 2011.
63. Haas S. Facts and artefacts of coagulation assays for factor Xa inhibitors. Thromb Haemost 2010; 103: 686-688.
64. Mannucci PM, Franchini M. Old and new anticoagulant drugs: A minireview. Ann Med 2011; 43: 116-123.
65. Massicotte MP, Sofronas M, deVeber G. Difficulties in performing clinical trials of antithrombotic therapy in neonates and children. Thromb Res 2006; 118: 153-163.
66. Massicotte P, Julian JA, Gent M, et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: The REVIVE trial. Thromb Res 2003; 109: 85-92.
67. Journeycake JM, Buchanan GR. Thrombotic complications of central venous catheters in children. Curr Opin Hematol 2003; 10: 369-374.
68. Filippi L, Palermo L, Pezzati M, et al. Paradoxical embolism in a preterm infant. Dev Med Child Neurol 2004; 46: 713-716.
69. Journeycake J. Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer (DVT). ClinicalTrialsgov: National Institutes of Health; 2011.
70. Journeycake JM, Buchanan GR. Catheter-related deep venous thrombosis and other catheter complications in children with cancer. J Clin Oncol 2006; 24: 4575-4580.
71. Journeycake JM, Eshelman D, Buchanan GR. Post-thrombotic syndrome is uncommon in childhood cancer survivors. J Pediatr 2006; 148: 275-277.
72. Kuhle S, Spavor M, Massicotte P, et al. Prevalence of post-thrombotic syndrome following asymptomatic thrombosis in survivors of acute lymphoblastic leukemia. J Thromb Haemost 2008; 6: 589-594.
73. Schmidt B, Andrew M. Neonatal thrombosis: Report of a prospective Canadian and international registry. Pediatrics 1995; 96: 939-943.
74. van Ommen CH, Heijboer H, Buller HR, et al. Venous thromboembolism in childhood: A prospective two-year registry in The Netherlands. J Pediatr 2001; 139: 676-681.
75. Dietrich JE, Yee DL. Thrombophilic conditions in the adolescent: The gynecologic impact. Obstet Gynecol Clin North Am 2009; 36: 163-175.
76. Briones M, Abshire T. Lupus anticoagulants in children. Curr Opin Hematol 2003; 10: 375-379.
77. Ravelli A, Martini A. Antiphospholipid syndrome. Pediatr Clin North Am 2005; 52: 469-491, vi.
78. Male C, Foulon D, Hoogendoorn H, et al. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005; 106: 4152-4158.
79. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
80. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-198S.
81. Ortel TL. The antiphospholipid syndrome: What are we really measuring? How do we measure it? And how do we treat it? J Thromb Thrombolysis 2006; 21: 79-83.
82. Raffini L, Thornburg C. Testing children for inherited thrombophilia: More questions than answers. Br J Haematol 2009; 147: 277-288.
83. Madani MM, Wittine LM, Auger WR, et al. Chronic thromboembolic pulmonary hypertension in pediatric patients. J Thorac Cardiovasc Surg 2011; 141: 624-630.
84. Johnson JN, Driscoll DJ, McGregor CG. Pulmonary thromboendarterectomy in adolescents and young adults. Pediatr Pulmonol 2010; 45: 614-618.
85. Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 2004; 351: 1081-1088.
86. Goldenberg NA, Tripputi M, Crowther M, et al. The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism. Contemp Clin Trials 2010; 31: 131-133.
87. Goldenberg NA. Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT). ClinicalTrials.gov: National Institutes of Health; 2011.
88. O'Brien SH. Secondary data demonstrate safety of splenectomy in spherocytosis. Pediatr Blood Cancer 2009; 52: 753-754.
89. Odegard KC, McGowan FXJr, Zurakowski D, et al. Coagulation factor abnormalities in patients with single-ventricle physiology immediately prior to the Fontan procedure. Ann Thorac Surg 2002; 73: 1770-1777.
90. Odegard KC, McGowan FXJr, Zurakowski D, et al. Procoagulant and anticoagulant factor abnormalities following the Fontan procedure: Increased factor VIII may predispose to thrombosis. J Thorac Cardiovasc Surg 2003; 125: 1260-1267.
91. Abbott LS, Deevska M, Fernandez CV, et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood 2009; 114: 5146-5151.
92. Giordano P, Molinari AC, Del Vecchio GC, et al. Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia. Am J Hematol 2010; 85: 325-330.
93. O'Brien SH, Klima J, Termuhlen AM, et al. Venous thromboembolism and adolescent and young adult oncology inpatients in US children's hospitals, 2001 to 2008. J Pediatr 2011; 159: 133-137.
94. Paz-Priel I, Long L, Helman LJ, et al. Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol 2007; 25: 1519-1524.
95. Dvorak HF. Thrombosis and cancer. Hum Pathol 1987; 18: 275-284.
96. Kerlin BA, Palumbo JS, Nicol K, et al. Tissue factor expression by common pediatric malignant tumors: A pilot feasibility study (abstract). Haemophilia 2009; 15: 1.
97. Kerlin BA, Blatt NB, Fuh B, et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: A Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr 2009; 155: 105-110, 110 e101.
98. Schlegel N. Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost 1997; 23: 271-280.
99. O'Brien SH. Decision analysis in pediatric hematology. Pediatr Clin North Am 2008; 55: 287-304, vii.
100. D'Agostino RB Jr. Propensity scores in cardiovascular research. Circulation 2007; 115: 2340-2343.
101. Winkelmayer WC, Kurth T. Propensity scores: Help or hype? Nephrol Dial Transplant 2004; 19: 1671-1673.
102. Mitchell LG, Goldenberg NA, Male C, et al. Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children. J Thromb Haemost 2011; 9: 1856-1858.
103. Faustino EV, Lawson KA, Northrup V, et al. Mortality-adjusted duration of mechanical ventilation in critically ill children with symptomatic central venous line-related deep venous thrombosis. Crit Care Med 2011; 39: 1151-1156.
104. Kuhle S, Koloshuk B, Marzinotto V, et al. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res 2003; 111: 227-233.
105. Kahn SR. How I treat postthrombotic syndrome. Blood 2009; 114: 4624-4631.
106. Biss TT, Kahr WH, Brandao LR, et al. The use of elastic compression stockings for post-thrombotic syndrome in a child. Pediatr Blood Cancer 2009; 53: 462-463.